Blue Cross Blue Shield/Blue Care Network of Michigan Medication Authorization Request Form



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For <u>commercial members only</u>, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION	PHYSICIAN INFORMATION
Name	Name
ID Number	Specialty
D.O.B. // MM/DD/YYYY	Address
Diagnosis	City /State/Zip
Drug Name Radicava	Phone:
Dose and Quantity	Fax: NPI
Directions	Contact Person
Date of Service(s)	Contact Person Phone / Ext.
STEP 1: DISEASE STATE INFORMATION	
Required Demographic Information:	
Patient Weight:kg	
Patient Height:ftinche	es
service area. If you are not a provider in the geographic so the FEP member's benefit requirements. Is this member's FEP coverage primary or secondary coverage If primary, continue with question set. If secondary, an authorization is not needed through	will be serviced by a provider within the health plan's geographic ervice area, please contact the health plan for questions regarding ge? ugh this process. Please contact the member's primary coverage for
determination of benefit and additional informat	10n.

	ria Questions: Does the patient have a diagnosis of amyotrophic lateral sclerosis ((ALS/Lou Gehrig's disease)? □Yes □No
2. Ha	as the patient been on Radicava therapy continuously for the last	6 months, excluding samples? Please select answer below:
	NO – this is INITIATION of therapy, please answer the follow	ving questions:
	a. Has the patient had a baseline evaluation of the condition usir Scale-Revised (ALSFRS-R) or Japanese ALS Severity Scale?	
	☐ ALS Functional Rating Scale-Revised (ALSFRS-R) i. Does the patient have a score of 2 or greater on ea	ach individual item of the scale? □Yes □No
	☐ Japanese ALS Severity Scale i. Does the patient have a grade of 1 or 2? ☐ Yes	□No
	□No	
	b. Does the patient have normal respiratory function defined as a ☐Yes ☐No	a forced vital capacity (FVC) greater than or equal to 80 percen
	c. Will this medication be used in combination with riluzole (Ri	lutek)? □Yes □No*
	*If NO, has the patient had an inadequate response to riluzole	e (Rilutek)? □Yes □No
	d. Is this medication being prescribed or recommended by a neu	rrologist? □Yes □No*
□YE	S – this is a PA renewal for CONTINUATION of therapy, plea	ase answer the following question:
	a. Is there documentation of stabilization, slowing of disease profollowing scoring tools: ALSFRS-R (ALS Functional Rating	ogression, or improvement of the condition using ONE of the Scale-Revised) or Japanese ALS Severity Scale? □Yes □No
notes are	required for the processing of all requests. Please add any other suppo Coverage will not be provided if the prescribing physician's sig	
lest for exped	ited review: I certify that applying the standard review time frame may seriously jeopardize the life or healt	th of the member or the member's ability to regain maximum function
ian's Nan		Date
2: :list	☐ Form Completely Filled Out ☐ Provide chart notes	☐ Attach test results
B: it	By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979	By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320